Target intelligence / Profile preview

Russell's viper venom factor X activator (RVV-X)

Target
RVV-X
Molecular classification
Enzyme, Metalloproteinase, Snake venom metalloproteinase (SVMP), Zinc endopeptidase, P-IIId class of SVMP
01

Overview

Russell's viper venom factor X activator (RVV-X) is a major, highly toxic zinc-dependent metalloproteinase found in the venom of Russell's viper (*Daboia russelii*). It belongs to the P-IIId class of snake venom metalloproteinases and is responsible for activating blood coagulation factor X by specific proteolytic cleavage, thereby initiating rapid clot formation, disseminated intravascular coagulation, and widespread tissue damage. The toxin contributes to multiple systemic pathologies following envenomation, making it a major drug and diagnostic target for antivenom development and laboratory detection of clotting disorders. Other minor toxins (such as various phospholipase A2 isoforms) exist in the venom, but RVV-X is the canonical therapeutic target.

Other names
RVV-XFactor X activating enzyme from Russell's viper venomRussell's viper factor X activatorSnake venom metalloproteinase (SVMP)P-IIId SVMP
02

Mechanism of action

RVV-X acts through enzymatic cleavage and activation of factor X at Arg194-Ile195. This is a Zn^2+-dependent hydrolysis reaction that initiates the coagulation cascade via direct factor X activation.

03

Biological functions

Activation of blood coagulation factor XInduction of abnormal blood clotting (procoagulant effect)Disruption of hemostasis (can be procoagulant or anticoagulant)Platelet aggregationEndothelial cell injuryTissue necrosisPro-inflammationMyonecrosisLocal and systemic hemorrhage
04

Disease associations

Hemostatic disorders (disseminated intravascular coagulation, DIC)Acute kidney injuryMuscle necrosisLocal tissue damageSystemic envenomingUsed diagnostically to detect lupus anticoagulant (autoimmune disorder)
05

Safety considerations

High toxicity, rapid blood coagulation, risk of disseminated intravascular coagulation (DIC)Local and systemic hemorrhageRenal failure, myonecrosisDifficulty neutralizing with antivenoms due to toxin heterogeneity
06

Interacting drugs

Polyvalent (and sometimes monovalent) antivenom

2 more in the full profile.

07

Biomarkers

dRVVT test for lupus anticoagulant (presence and efficacy)Factor X activity in plasma (can indicate toxin exposure)

Beyond the preview

Go deeper on Russell's viper venom factor X activator (RVV-X).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Russell's viper venom factor X activator (RVV-X).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call